| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
47,361,000 |
| Market
Cap: |
722.26(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$15.25 - $15.25 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Aerie Pharmaceuticals is a pharmaceutical company focused on the discovery, development and commercialization of ophthalmic therapies for the treatment of patients with eye diseases and conditions including open-angle glaucoma, dry eye, and diabetic macular edema. Rhopressa® is a once-daily eye drop designed to reduce elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Rocklatan® is a once-daily fixed-dose combination of Rhopressa® and latanoprost, a prescribed drug for the treatment of patients with open-angle glaucoma or ocular hypertension. Co. is developing AR-15512, an ophthalmic solution for the treatment of patients with dry eye disease.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Mitro Thomas A |
President and COO |
• – – |
2020-02-24 |
4 |
D |
$20.30 |
$20,848 |
D/D |
(1,027) |
79,569 |
|
- |
|
| Rubino Richard J |
Chief Financial Officer |
• – – |
2020-02-24 |
4 |
D |
$20.30 |
$17,397 |
D/D |
(857) |
347,851 |
|
- |
|
| Kopczynski Casey C. |
Chief Scientific Officer |
• – – |
2020-02-24 |
4 |
D |
$20.30 |
$13,581 |
D/D |
(669) |
226,114 |
|
- |
|
| Anido Vicente Jr |
Chief Executive Officer |
• • – |
2020-02-23 |
4 |
D |
$21.59 |
$22,713 |
D/D |
(1,052) |
221,323 |
|
- |
|
| Mitro Thomas A |
President and COO |
• – – |
2020-02-23 |
4 |
D |
$21.59 |
$16,473 |
D/D |
(763) |
80,596 |
|
- |
|
| Rubino Richard J |
Chief Financial Officer |
• – – |
2020-02-23 |
4 |
D |
$21.59 |
$8,852 |
D/D |
(410) |
348,708 |
|
- |
|
| Kopczynski Casey C. |
Chief Scientific Officer |
• – – |
2020-02-23 |
4 |
D |
$21.59 |
$7,082 |
D/D |
(328) |
226,783 |
|
- |
|
| Larocca John |
General Counsel |
• – – |
2020-02-19 |
4 |
D |
$19.47 |
$30,023 |
D/D |
(1,542) |
32,723 |
|
- |
|
| Mitro Thomas A |
President and COO |
• – – |
2020-02-08 |
4 |
D |
$20.49 |
$24,240 |
D/D |
(1,183) |
81,359 |
|
- |
|
| Anido Vicente Jr |
Chief Executive Officer |
• • – |
2020-02-08 |
4 |
D |
$20.49 |
$31,678 |
D/D |
(1,546) |
222,375 |
|
- |
|
| Kopczynski Casey C. |
Chief Scientific Officer |
• – – |
2020-02-08 |
4 |
D |
$20.49 |
$14,343 |
D/D |
(700) |
227,111 |
|
- |
|
| Rubino Richard J |
Chief Financial Officer |
• – – |
2020-02-08 |
4 |
D |
$20.49 |
$20,961 |
D/D |
(1,023) |
349,118 |
|
- |
|
| Mitro Thomas A |
President and COO |
• – – |
2020-02-07 |
4 |
D |
$20.49 |
$26,780 |
D/D |
(1,307) |
82,542 |
|
- |
|
| Anido Vicente Jr |
Chief Executive Officer |
• • – |
2020-02-07 |
4 |
D |
$20.49 |
$35,038 |
D/D |
(1,710) |
223,921 |
|
- |
|
| Larocca John |
General Counsel |
• – – |
2020-02-07 |
4 |
D |
$20.49 |
$14,200 |
D/D |
(693) |
34,265 |
|
- |
|
| Kopczynski Casey C. |
Chief Scientific Officer |
• – – |
2020-02-07 |
4 |
D |
$20.49 |
$14,343 |
D/D |
(700) |
227,811 |
|
- |
|
| Rubino Richard J |
Chief Financial Officer |
• – – |
2020-02-07 |
4 |
D |
$20.49 |
$21,617 |
D/D |
(1,055) |
350,141 |
|
- |
|
| Mitro Thomas A |
President and COO |
• – – |
2020-02-06 |
4 |
A |
$0.00 |
$0 |
D/D |
14,000 |
83,849 |
|
- |
|
| Anido Vicente Jr |
Chief Executive Officer |
• • – |
2020-02-06 |
4 |
A |
$0.00 |
$0 |
D/D |
28,000 |
225,631 |
|
- |
|
| Rubino Richard J |
Chief Financial Officer |
• – – |
2020-02-06 |
4 |
A |
$0.00 |
$0 |
D/D |
11,750 |
351,196 |
|
- |
|
| Larocca John |
General Counsel |
• – – |
2020-02-06 |
4 |
A |
$0.00 |
$0 |
D/D |
3,500 |
34,958 |
|
- |
|
| Kopczynski Casey C. |
Chief Scientific Officer |
• – – |
2020-02-06 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
228,511 |
|
- |
|
| Anido Vicente Jr |
Chief Executive Officer |
• • – |
2020-01-28 |
4 |
A |
$0.00 |
$0 |
I/I |
2,250 |
10,500 |
|
- |
|
| Tananbaum James B. |
10% Owner |
– – • |
2019-12-20 |
4 |
OE |
$30.00 |
$867,000 |
I/I |
28,900 |
1,501,400 |
|
- |
|
| Kopczynski Casey C. |
Chief Scientific Officer |
• – – |
2019-12-03 |
4 |
OE |
$0.41 |
$47,385 |
D/D |
117,000 |
218,511 |
|
- |
|
333 Records found
|
|
Page 5 of 14 |
|
|
